Literature DB >> 30315667

Emergency response of four transfusion centers during the last Chikungunya outbreak in Italy.

Luca Pierelli1,2, Michele Vacca2, Gina Zini3, Maddalena Maresca3, Giacomo Menichella4, Susanna Santinelli4, Maria Alba Stigliano5, Gabriele Mandarello6, Roberto Gasbarri6, Stefania Vaglio7.   

Abstract

Between September 15 and November 11, 2017, the area of Rome was subjected to cessation of donation in an area of approximately 1,300,000 inhabitants and with a 5-day quarantine for the rest of metropolitan areas due to Chikungunya virus (CHIKV) outbreak. Quarantine was applied to red blood cell (RBC) and plasma units while platelet concentrates (PCs) were subjected to pathogen inactivation methods (PIMs). Quarantine was based on an active recall of all donors and, in case of declared absence of any symptom or illness, on release of RBC and plasma units after 5 days. Four regional centers in which PIMs were already performed were charged for PIMs for the rest of Rome's area. These centers increased by 236% their previous PIM procedures, producing additional 1425 pathogen-reduced (PR) PCs in 57 days, beside their production (996 PR PCs) for local needs. The emergency support was close to the maximal production capacity of the four centers and was successful only thanks to the limited length of emergency. No adverse events were reported by all centers through a passive hemovigilance approach and by a follow-up of approximately 4 months. None of the donors referred symptoms or illness at recall and none of the blood products were discarded after quarantine. To date, no cases of CHIKV-transmitted infection were reported in transfused patients. This experience has taught some relevant strategic and organizing aspects that should be taken into account when an infectious outbreak must be faced in a large metropolitan area.
© 2018 AABB.

Entities:  

Mesh:

Year:  2018        PMID: 30315667     DOI: 10.1111/trf.14892

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

1.  Cost of pathogen reduction for platelets: reply to Cicchetti et al. Blood Transfus 2018; 16: 483-9.

Authors:  Albert Farrugia
Journal:  Blood Transfus       Date:  2018-11-07       Impact factor: 3.443

Review 2.  A comparative analysis of the 2007 and 2017 Italian chikungunya outbreaks and implication for public health response.

Authors:  Beniamino Caputo; Gianluca Russo; Mattia Manica; Francesco Vairo; Piero Poletti; Giorgio Guzzetta; Stefano Merler; Carolina Scagnolari; Angelo Solimini
Journal:  PLoS Negl Trop Dis       Date:  2020-06-11

3.  Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storage.

Authors:  Jose A Cancelas; Jamie R Genthe; Moritz Stolla; Neeta Rugg; S Lawrence Bailey; Shawnagay Nestheide; Beth Shaz; Samantha Mack; Kadi Schroeder; Waseem Anani; Zbigniew M Szczepiorkowski; Larry J Dumont; Subramanian Yegneswaran; Laurence Corash; Nina Mufti; Richard J Benjamin; Anna C Erickson
Journal:  Transfusion       Date:  2022-07-09       Impact factor: 3.337

4.  Mitigating the risk of transfusion-transmitted infections with vector-borne agents solely by means of pathogen reduction.

Authors:  Susan L Stramer; Marion C Lanteri; Jaye P Brodsky; Gregory A Foster; David E Krysztof; Jamel A Groves; Rebecca L Townsend; Edward Notari; Sonia Bakkour; Mars Stone; Graham Simmons; Bryan Spencer; Laura Tonnetti; Michael P Busch
Journal:  Transfusion       Date:  2022-06-21       Impact factor: 3.337

Review 5.  Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.

Authors:  Marion C Lanteri; Felicia Santa-Maria; Andrew Laughhunn; Yvette A Girard; Marcus Picard-Maureau; Jean-Marc Payrat; Johannes Irsch; Adonis Stassinopoulos; Peter Bringmann
Journal:  Transfusion       Date:  2020-04-24       Impact factor: 3.157

6.  Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen-reduction technology.

Authors:  Yvette A Girard; Felicia Santa Maria; Marion C Lanteri
Journal:  Transfusion       Date:  2020-01-20       Impact factor: 3.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.